CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

176 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DPIK3CAE545KPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAWildtypePredictiveDoes Not SupportSensitivity/ResponseColorectal CancerAspirinLiao et al., 2012
DPIK3CAC420RPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
BPIK3CAMutationPredictiveSupportsResistanceBreast CancerTrastuzumabRazis et al., 2011
DPIK3CAH1047LPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
BPIK3CAMutationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabRazis et al., 2011
DPIK3CAH1047RPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAMutationPrognosticSupportsPoor OutcomeColorectal CancerKato et al., 2007
CPIK3CAE545QPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
CPIK3CAE545KPredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
DPIK3CAC420RPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinib,ErlotinibLudovini et al., 2011
DPIK3CAK111NPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
DPIK3CAI391MPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseCervix CarcinomaCisplatin,PictilisibArjumand et al., 2016
DPIK3CAE545KPredictiveSupportsResistanceCervical CancerCisplatinArjumand et al., 2016
DPIK3CAH1047RPredictiveSupportsResistanceColorectal CancerVemurafenibYang et al., 2012
CPIK3CAR88QPredictiveDoes Not SupportResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CPIK3CAH1047RPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CPIK3CAG1049RPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
CPIK3CAE542KPredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
CPIK3CAH1047LPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CPIK3CAS158LPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
BPIK3CAMutationPrognosticSupportsBetter OutcomeBreast CancerPérez-Tenorio et al., 2007
BPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseEstrogen-receptor Positive Breast CancerTamoxifenPérez-Tenorio et al., 2007
BPIK3CAE542K OR PIK3CA E545K OR PIK3CA H1047RPredictiveDoes Not SupportResistanceBreast CancerFEC Regimen,FAC RegimenLiedtke et al., 2008
DPIK3CAH1047RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinibEichhorn et al., 2008
DPIK3CAH1047RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinibEichhorn et al., 2008
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinib,TrastuzumabEichhorn et al., 2008
DPIK3CAE545KPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerDactolisibEichhorn et al., 2008
BPIK3CAMutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerSouglakos et al., 2009
BPIK3CAMutationPredictiveDoes Not SupportResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BPIK3CAMutationPredictiveDoes Not SupportResistanceColorectal CancerIrinotecanSouglakos et al., 2009
BPIK3CAMutationPredictiveDoes Not SupportResistanceColorectal CancerBevacizumabSouglakos et al., 2009
BPIK3CAMutationPredictiveSupportsResistanceColorectal CancerCetuximabSouglakos et al., 2009
BPIK3CAMutationPredictiveSupportsResistanceColorectal CancerCetuximab,PanitumumabSartore-Bianchi et al., 2009
BPIK3CAMutationPredictiveSupportsSensitivity/ResponseColorectal CancerAspirinLiao et al., 2012
BPIK3CAMutationPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaAspirin,Celecoxib,SulindacHedberg et al., 2019
BPIK3CAExon 21 Mutation OR PIK3CA Exon 10 MutationPrognosticSupportsPoor OutcomeRectum CancerHe et al., 2009
APIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerAlpelisib,FulvestrantAndré et al., 2019
DPIK3CAE545KPredictiveSupportsResistanceCervical CancerCisplatin,Ionizing RadiotherapyArjumand et al., 2016
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Akt Inhibitor MK2206Yang et al., 2012
BPIK3CAMutationPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
BPIK3CAMutationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerCapecitabine,LapatinibBaselga et al., 2016
CPIK3CAL938*PredictiveDoes Not SupportResistanceColorectal CancerCetuximabXu et al., 2017
BPIK3CAMutationPredictiveSupportsSensitivity/ResponseCancerCopanlisibDamodaran et al., 2022
CPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseCancerTaselisibKrop et al., 2022
APIK3CAMutation OR PTEN Mutation OR AKT1 MutationPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,CapivasertibTurner et al., 2023
Page 2 of 4
PreviousNext